INTRODUCTION
with untreated OSA show abnormal CPET responses compared to age-, activity-, and weight-matched controls without OSA. These abnormal CPET responses are reduced cardiorespiratory fitness (V'O 2 ), exaggerated systolic (SBP) and/or diastolic blood pressure (DBP), chronotropic impairment (e.g. high HR reserve), impaired ventilatory equivalents for oxygen (V'E/V'O 2 ), impaired ventilatory equivalents for carbon dioxide (V'E/V'CO 2 ) at submaximal and maximal workloads, and blunt heart rate recovery (HRR) at peak exercise (Aron, Zedalis, Gregg, Gwazdauskas, & Herbert, 2009; Grote, Hedner, & Peter, 2004; Hargens et al., 2009; Nanas et al., 2010; Vanhecke et al., 2008) . However, a few studies have reported similar V'O 2peak , HR reserve, SBP, and DBP at peak exercise between OSA patients and controls (Alonso-Fernandez et al., 2006; Hargens et al., 2008; Kaleth et al., 2007) .
Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA patients. Proper CPAP use results in significant clinical benefits, such as reduced inflammation, oxidative stress, and cardio-metabolic risk (McDaid et al., 2009) . The mechanism by which CPAP treatment improves cardiovascular performance during maximum exercise in OSA patients is unclear. Following two months of CPAP treatment, patients with severe OSA show increased exercise capacity (e.g. increases in V'O 2 , workload, and oxygen pulse at peak exercise) as well as an increase in anaerobic threshold (Lin, Lin, Wu, & Chou, 2004) . However, studies in patients with mild to moderate OSA found no beneficial effect of CPAP treatment on exercise capacity (Edward Shifflett, Walker, Gregg, Zedalis, & Herbert, 2001; Maeder et al., 2009; Pendharkar, Tsai, Eves, Ford, & Davidson, 2011) . We therefore investigated whether the CPET responses of OSA patients were lower compared to a control group of age-and BMI-matched adults without OSA, and whether cardiovascular performance were improved following 180 days of CPAP treatment in severe OSA patients.
METHODS

Study Subjects
This study was non-randomized and open-labeled. A total of 80 subjects consisting of 40 healthy subjects and 40 severe OSA patients were included in this study. Each group had 15 males and 25 females aged 30 years or older. Forty healthy subjects (control group) with no history of OSA and Epworth Sleepiness Scale (ESS) of less than five were recruited from the healthy Thai population in Khon Kaen Province, Thailand. Subjects with a history of smoking, cardiovascular, neuromuscular, or pulmonary disease, severe microvascular diabetic complications, diabetes mellitus, hypertension (blood pressure ≥ 140/90 mm Hg), or arthritis were excluded from the study.
Forty severe OSA patients who were newly diagnosed by medical specialists using polysomnography (PSG) within the month preceding the beginning of the study were recruited from the Sleep Disorder Clinic at Srinagarind Hospital, Khon Kaen, Thailand. OSA patients had an apnea-hypopnea index (AHI) of at least thirty events per hour and no history of treatment for OSA with CPAP or oral devices, tracheostomy, or use of oxygen therapy at home. All subjects underwent screening for medical history by a physician. Patients with a history of cardiovascular disease, autoimmune conditions, diabetes mellitus, or symptoms of respiratory tract infection in the six weeks prior to the study were excluded. Patients chose to enroll in either the CPAP treatment (CPAP group, n = 20) or non-CPAP treatment group (n = 20). Patients received a general health care treatment program for OSA, including nasal spray for nasal allergies.
The purpose, benefits, and possible risks associated with the study were explained to the subjects and informed consent was obtained, in accordance with the Khon Kaen University Ethics Committee for Human Research (approval numbers HE591202).
Polysomnography
OSA patients underwent full-night PSG using a digital system at the Sleep Disorder Clinic, Faculty of Medicine (Srinagarind Hospital, Khon Kaen University). PSG was performed using a procedure described previously (Tichanon et al., 2016) . Apnea was defined as a decrease in amplitude of airflow of at least 90% for at least 10 seconds and continued respiratory effort. Similarly, hypopnea was defined as a reduction in airflow of at least 30% that coincided with a decrease in oxygen desaturation of at least 3% and/or the event associated with an arousal (Heinrich, Spiesshofer, Bitter, Horstkotte, & Oldenburg, 2015) . The respiratory effort-related arousal (RERA) is defined as increased respiratory effort or flattening of the nasal pressure waveform, leading to an arousal in which the sequence of breaths does not meet the criteria for hypopnea. The respiratory disturbance index (RDI) is defined as the average number of respiratory disturbances (obstructive apneas, hypopneas, and RERA) per hour (Masa et al., 2009 ).
CPAP therapy and follow up CPAP (DeVilbiss IntelliPAP AutoAdjust, USA) was administered during sleep at night for at least five hours per night, for at least five days per week, and for 180 consecutive days. The patients came for a follow up visit every month, during which average hours of nightly use (h) and average days per week (days/week) of CPAP therapy for each patient were recorded from the CPAP device. The range of optimal CPAP pressure was adjusted manually each month if necessary.
Cardiopulmonary exercise testing (CPET)
All subjects (control, CPAP, and non-CPAP groups) performed an incremental exercise test on a treadmill (Stationary Cardiopulmonary exercise testing, Cosmed, Quark CPET, Italy) (Day 0). Subjects were instructed not to engage in any intense physical activity in the four hours before testing, or to consume food or caffeinated beverages in the two hours before testing (Mohammad, Dadashpour, & Adimi, 2012) . The protocol for CPET was determined based on age, weight, height, gender, and work rate (WR), according to the method described by Porszasz and colleagues (Porszasz, Casaburi, Somfay, Woodhouse, & Whipp, 2003) . The protocol used was described previously (Tichanon Promsrisuk, 2017) . All tests were performed in a room in which the temperature was kept at 25 o C, according to current guidelines for exercise testing (Chest., 2003) . Expired ventilation (V'E), oxygen consumption (V'O 2 ), carbon dioxide production ( V'CO 2 ), ECG, and oxygen saturation (SpO 2 ) were monitored continuously and blood pressure was measured every minute. Cardiac output (CO) and stroke volume (SV) were automatically calculated via COSMED software during CPET. The test was performed under the supervision of a physician. The test was terminated in the case of dyspnea, leg fatigue, disabling symptoms, at the request of the subject, or by the investigator for safety reasons, according to previously described criteria for termination of the test (Edvardsen, Hem, & Anderssen, 2014) . HRR was defined as the difference in beats/min between HR after maximal exercise (HR max exer ) and HR at 1 to 5 min into recovery. Only subjects belonging to CPAP and non-CPAP groups performed CPET at Day 180.
The presence of three or more of the following criteria was used to define maximal exercise: a plateau in V'O 2 , HR greater than 90% of the predicted maximum HR (HR max-age , defined as 220 -age of subject), respiratory exchange ratio (RER) of more than 1.15, request by the subject to stop because of maximal voluntary fatigue, and a score of 18 points or more on the Borg rating of perceived exertion (RPE) scale. The highest V'O 2 value during 30-sec stage was used. The V'O 2 plateau was defined as any two 30-sec V'O 2 values in which the second was less than or equal to the first, provided ventilation was at maximal effort (Nogueira & Pompeu, 2006) .
Statistical Analyses
Statistical analyses were performed using STATA version 13.0 (StataCorp, College Station, TX). Data were expressed as mean and standard deviation (SD). The relationship between severity of OSA (AHI) and V'O 2max was determined by multiple linear regressions. An unpaired t-test was used to compare OSA patients and healthy subjects with respect to anthropometric features, clinical characteristics, CPET parameters, and HRR on Day 0. A paired T-test was used to compare CPAP parameters, CPET parameters and HRR between Day 0 and 180 of CPAP therapy in both CPAP and non-CPAP groups. A value of p < 0.05 was considered statistically significant. Table 1 shows average normal ranges of baseline demographic data in 40 controls and 40 OSA patients including 15 males and 25 females in each group. OSA patients had higher ESS (p < 0.001), SBP (p < 0.01), DBP (p < 0.05), and mean arterial pressure (MAP) (p < 0.001). No significant differences in these parameters between patients in CPAP (six males & 14 females) and non-CPAP (nine males & 11 females) treatment groups were found.
RESULTS
PSG data for subjects in CPAP and non-CPAP treatment groups (Day 0) and CPAP parameters for subjects in the CPAP treatment group on Day 180 are shown in Table 2 . AHI, respiratory effort related arousals (RERA), respiratory disturbance index (RDI), arousal index, apnea index, and lowest SpO 2 of subjects in the CPAP group did not differ from those in the non-CPAP treatment group. The average CPAP usage indices for Day 180 of 86.0 ± 6.0%, average nightly use of approximately seven hours per night indicate adequate CPAP use. The average CPAP pressure was 13.2 ± 1.6 cmH 2 O. AHI as measured by CPAP device gradually decreased over time following CPAP treatment (p < 0.001, p < 0.05) but no changes in other CPAP parameters were observed.
CPET parameters in controls, OSA patients, and the subgroups CPAP, and non-CPAP treatment groups at maximal exercise are shown in Table 3 and Figure 1 . On Day 0, ventilatory efficiency, as measured by V'E/V'O 2 and V'E/V'CO 2 , was greater in OSA patients compared to controls (p < 0.01 and p < 0.001, respectively). SBP was higher while V'CO 2 was lower in OSA patients compared to controls (p < 0.01 and p < 0.05, respectively). HR at maximum exercise was significantly lower in OSA patients (p < 0.001) and therefore HR reserve was higher (p < 0.001) compared to controls. V'O 2 max as measured in ml/ min (17.4%), ml/kg/min (32.9%), and %predicted 14.4%) was significantly lower in OSA patients compared to controls (p < 0.001) (Figure 1 ).
In the CPAP treatment group, subjects showed decreased HR reserve (p < 0.001), increased CO (p < 0.01), and decreased SBP (p < 0.001) on Day 180 compared to Day 0 (Table 3) . Interestingly, V'O 2 max in ml/min, ml/kg/min, and % predicted increased by 3.8%, 3.9%, and 4%, respectively, after 180 days of CPAP V'E/V'O 2 32.8 ± 4.6 37.7 ± 9.0** 37.8 ± 8.5 37.7 ± 8.6 37.7 ± 9.7 37.7 ± 9.7 V'E/V'CO 2 29.7 ± 3.2 33.5 ± 3.3*** 33.9 ± 4.0 33. (Table 3) . However, SV (p < 0.05) and SpO 2 (p < 0.01) on Day 180 significantly decreased compared to Day 0 (Table 3) . Linear regression analysis showed a negative correlation between AHI and V'O 2max (R 2 = 0.1363, p < 0.05) (Figure 3) . Moreover, AHI was negatively correlated with V'O 2max with age and adjusted BMI (data not shown).
Average HRR was blunted, as evidenced by higher recovery time at min 1 to 5 in OSA patients compared to controls (Table 4) (p < 0.001). Improvement in HRR after 180 consecutive days of CPAP treatment was observed (p < 0.01). There were no differences in HRR between Day 0 and Day 180 in the non-CPAP group.
DISCUSSION
The main findings of this study were that (i) severe OSA patients had significantly higher SBP, DBP, and MAP at rest, significantly higher V'E/V'CO 2 , V'E/V'O 2 , and HR reserve, and significantly lower V'O 2max during maximal exercise compared to those of controls; (ii) OSA patients had blunted HRR at one to five minutes after maximum exercise compared to control group; (iii) after CPAP therapy characterized by 86 ± 6% of CPAP usage index and 7.0 ± 0.5 h/night for 180 days, significant improvements in V'O 2 max, HR reserve, HRR were observed; (iv) SV and SpO 2 were preserved in CPAP treatment group, whereas they were lowered in non-CPAP group after 180 days.
The finding that OSA patients have significantly higher blood pressure in MAP at rest is in agreement with some previous studies (Kaleth et al., 2007; Nelesen et al., 1996) . However, other studies found no difference in MAP between OSA patients and controls (Hargens et al., 2008; Kline et al., 2013; Tichanon et al., 2016) . It is probable that this discrepancy is related to severity of OSA, with severe OSA resulting in higher MAP but mild to moderate OSA causing no measurable effect on MAP. OSA is a recognized cause of hypertension (Dopp, Reichmuth, & Morgan, 2007) . OSA episodes produce increases in SBP and DBP and hence MAP. The possible mechanisms responsible for this hypertension include intermittent hypoxemia inducing arousal (Becker et al., 2003) , sympathetic overactivity (Kline et al., 2013) , increased oxidative stress (4), and increased mediators of inflammation (Ryan et al., 2005) . In addition, intermittent 51.5 ± 13.5 4.6 ± 3.7*** 4.2 ± 3.3 18.6 ± 8.5 ### 5.1 ± 4.2 5.9 ± 4.6 HRR2 (/min) 58.0 ± 13.5 10.9 ± 4.5*** 10.2 ± 4.7 27.0 ± 9.8 ### 11.6 ± 4.4 12.3 ± 4.2 HRR3 (/min) 69.9 ± 15.4 21.8 ± 6.3*** 20.9 ± 6.5 42.0 ± 15.7 ### 22.7 ± 6.1 23.3 ± 5.5 HRR4 (/min) 77.6 ± 14.6 31.8 ± 7.2*** 31.0 ± 7.6 51.1 ± 15.9 ### 32.6 ± 6.9 33.5 ± 5.7 HRR5 (/min) 82.0 ± 13.5 36.2 ± 8.2*** 35.5 ± 8.9 56.8 ± 17.6 ### 36.8 ± 8.1 38.0 ± 7.1
Data are expressed as mean ± SD. OSA: obstructive sleep apnea; CPAP: continuous positive airway pressure; HR max exer ; maximum heart rate during exercise; HRR: heart rate recovery. ***p < 0.001 Non-OSA vs. OSA patients, ### p < 0.001 pre vs. post in CPAP treatment group.
hypoxemia also stimulates chemoreflex function, angiotensin II, and endothelin I release (Nelesen et al., 1996) which consequently leads to vasoconstriction. We observed a significantly lower V'O 2max in patients with OSA compared to controls. This result agrees with previous studies (Lin et al., 2004; Nanas et al., 2010) . Nevertheless, other studies found no evidence of reduced V'O 2max in OSA patients (Hargens et al., 2008; Kaleth et al., 2007) . Mechanisms responsible for reduced V'O 2max in OSA patients remain unclear. One potential contributing factor is hypoxia-induced oxidative stress, which leads to mitochondrial damage (Ryan et al., 2005) and/or decreases in number of type I fibers and mitochondria (Nanas et al., 2010) , ultimately resulting in deficit in oxidative capacity (Hargens et al., 2009 ). In OSA patients, an increased sympathetic drive from arousal during sleep may induce increased catecholamine release during vigorous exercise (Nanas et al., 2010) . Consequently, this may cause increased total peripheral resistance (Kline et al., 2013) , lack of blood supply to muscle fibers, and finally a decrease in V'O 2max (Vanuxem et al., 1997) .
In the present study, we found that sleep apnea severity index (AHI) was negatively correlated with V'O 2max . To our knowledge, there was one study done in mild OSA patients only (Przybylowski et al., 2007) , while the present study and other studies were conducted in severe or moderate to severe OSA patients (Cintra et al., 2009; Vanhecke et al., 2008) . This discrepancy is probably due to differences in the severity of OSA patients included in each study.
The higher V'E/V'CO 2 and V'E/V'O 2 found in the OSA patients during maximal exercise were due to lowered V'CO 2 , lowered V'O 2 , and a slight but not significant increase in V'E compared to controls. This finding is in agreement with a previous study (Hargens et al., 2009) . However, other studies reported similar V'E/V'CO 2 and V'E/V'O 2 at maximal exercise compared to OSA patients (Innocenti Bruni, Gigliotti, & Scano, 2012; Kline et al., 2013; Lin et al., 2004) . The higher V'E/V'CO 2 and V'E/ V 'O 2 during maximal exercise might be due to sympathetic activity-induced increase ventilation drive (Kaleth et al., 2007) and mitochondrial dysfunction (Nanas et al., 2010; Ryan et al., 2005) . The latter then promotes anaerobic metabolism (Hargens et al., 2009 ), leading to stimulating ventilation via carotid body chemoreceptors and ventilation.
We also found lower HR and hence higher HR reserve at maximal exercise in OSA patients compared to controls, which is in agreement with another study in OSA patients showing a lower average HR across all levels of exercise, including maximal exercise (Kaleth et al., 2007) . In contrast, other studies observed that OSA patients had similar HR at maximal exercise intensity to controls (Kline et al., 2013; Nanas et al., 2010) . This disagreement may be due to the fact that their studies were done in patients with mild to moderate OSA, while this study was carried out in patients with severe OSA. Sleep fragmentation and hypoxia cause autonomic dysfunction and ventricular dysfunction (Kaleth et al., 2007) , both of which induce exercise tolerance limitation and early occurrence of dyspnea and limb muscle fatigue, and therefore the lower V'O 2max found in the present study (Przybylowski et al., 2007; Quadri et al., 2017) . One potential consequence is that β-adrenergic receptors are down regulated, resulting in an inability to elevate HR sufficiently to quickly meet the physiological demands imposed by exercise, and finally an increase in HR reserve (Kaleth et al., 2007) .
Another noteworthy observation made in our study was the delayed HRR after maximal exercise in severe OSA patients compared to controls, which is consistent with previous observations (Grote et al., 2004; Kline et al., 2013; Nanas et al., 2010) . One previous study failed to find a blunted HRR to exercise in OSA patients in mild OSA patients (Hargens et al., 2008) . The blunted HRR we observed in severe OSA patients could be due to an abnormal parasympathetic activity (Grote et al., 2004; Kline et al., 2013; Nanas et al., 2010) and/or autonomic imbalance (Santamit et al., 2015) .
The present study showed significant improvements in V'O 2max and CO in OSA patients following 180 days of CPAP treatment. Previous studies have demonstrated that CPAP treatment for 60 to 180 days improved exercise capacity, as reflected by an increase in V'O 2max and maximum workload (Lin et al., 2004; Maeder et al., 2009; Quadri et al., 2017) . However, another study found no evidence of increased V'O 2max following CPAP treatment for 90 days (Pendharkar et al., 2011) . A possible explanation for the increased V'O 2 observed in the present study is that CPAP reduces oxidative stress and inflammation leading to improving cardiac function, as evidenced by increased CO after 180 days of CPAP treatment.
Oxygen consumption is regulated by three mechanisms: V'E, CO, and mitochondrial metabolism (Chest, 2003) . Cardiovascular function is the major limiting factor for exercise in OSA patients, as opposed to impairment of ventilation or ventilatory responses to exercise (Evans, Selvadurai, Baur, & Waters, 2014) . Impaired CO response to an exercise stress test may also be a consequence of intermittent hypoxia during sleep. This study found significant improvements in V'O 2max of approximately 4% after treatment with CPAP therapy for 180 days. Moreover, it is likely that CPAP therapy improves CO (Quadri et al., 2017) and metabolism in mitochondria of muscle cells (Kline et al., 2013) . Longitudinal research is needed to evaluate the effect of CPAP on V'O 2max and cardiovascular adaptation in OSA patients.
In this study, we administered CPAP for 180 days and measured HR reserve at maximal exercise before and after CPAP treatment. HR reserve improvement resulting from CPAP therapy is an effective treatment for sympathetic overactivity (Quadri et al., 2017; Santamit et al., 2015) and oxidative stress (Tichanon et al., 2016) . CPAP therapy is also effective in increasing HR at maximal exercise. The improved HR reserve at maximal exercise observed was possibly due to CPAP reducing or eliminating episodes of apnea and arousal.
This study also demonstrated improvement in HRR in severe OSA patients after 180 days of CPAP therapy, which agrees with the majority of other studies (Maeder et al., 2009; Quadri et al., 2017) . CPAP therapy is effective in suppressing sympathetic nerve activity (Santamit et al., 2015) and improved chronotropic control during exercise (Quadri et al., 2017) . Adequate CPAP use (approximately seven hours per night) in OSA patients resulted in improved HRR.
CONCLUSIONS
The present study found clinical benefits of adequate CPAP use (usage index of 86 ± 6% and 7.0 ± 0.5 h/night for six consecutive months) in treating severe OSA patients, as evidenced by improved cardiovascular performance. We found increased oxygen capacity, increased cardiac output, decreased SBP, improved HRR, and improved HR reserve.
